Trials / Terminated
TerminatedNCT04555096
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Galera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GC4419 | 180 Minute IV Infusion |
| DRUG | Placebo | 180 Minute IV Infusion |
Timeline
- Start date
- 2020-09-09
- Primary completion
- 2021-05-28
- Completion
- 2021-05-28
- First posted
- 2020-09-18
- Last updated
- 2022-03-18
- Results posted
- 2022-03-18
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04555096. Inclusion in this directory is not an endorsement.